Impaired counterregulation during hypoglycemia in type 1 diabetes (T1D) is partly
attributable to inadequate glucagon secretion. Intra-islet somatostatin (SST) suppression of …

Diminished responsiveness to hypoglycemia contributes to defective counterregulation in
diabetes. Pancreatic and/or circulating somatostatin are elevated in diabetes, which may …

Selective antagonism of somatostatin receptor type 2 (SSTR2) normalizes glucagon and
corticosterone responses to hypoglycemic clamp in diabetic rats. The purpose of this study …

Recent antecedent hypoglycemia is a known source of defective glucose counter-regulation
in diabetes; the mechanisms perpetuating the cycle of progressive α-cell failure and …

Incretin and insulin responses to nutrient loads are suppressed in persons with diabetes,
resulting in decreased glycemic control. Agents including sulfonylureas and dipeptidyl …

Somatostatin (SST) potently inhibits insulin and glucagon release from pancreatic islets.
Five distinct membrane receptors (SSTR1–5) for SST are known, and at least two (SSTR2 …

Somatostatin (SS) inhibits glucagon-like peptide-1 (GLP-1) secretion in a paracrine manner.
We hypothesized that blocking somatostatin subtype receptor 2 (SSTR2) and 5 (SSTR5) …

Somatostatin (SST) peptide is a potent inhibitor of insulin secretion and its effect is mediated
via somatostatin receptor 5 (SSTR5) in the endocrine pancreas. To investigate the …

Somatostatin inhibits both glucagon and insulin secretion. Glucagon significantly contributes
to hyperglycemia in type 2 diabetes. Despite its function in the inhibition of glucagon …

Exogenously administered somatostatin (SST) inhibits secretion of insulin and glucagon.
Furthermore, it is hypothesized that islet SST regulates glucagon secretion by a local action …